Synapse - Works

Results (19)

Impact of early histological transformation on survival in patients with follicular lymphoma

Meeting Abstract

Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
Blood (2023)

Fulltext@MSK | Save

Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome

Meeting Abstract

Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J. R.; Devlin, S. M.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Wills, B.; Tomas, A. A.; more...
Blood (2023)

Fulltext@MSK | Save

A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma

Meeting Abstract

Park, J. H.; Palomba, M. L.; Devlin, S. M.; Valtis, Y. K.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E.; Liotta, K.; Yu, A.; more...
Blood (2023)

Fulltext@MSK | Save

18F-FDG PET/CT imaging biomarkers for car-T cell therapy outcomes in large-B-cell lymphoma

Meeting Abstract

Leithner, D.; Flynn, J. R.; Devlin, S. M.; Mauguen, A.; Fei, T.; Zeng, S.; Imber, B. S.; Hubbeling, H.; Mayerhoefer, M.; Luttwak, E.; more...
Blood (2023)

Fulltext@MSK | Save

Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
Blood (2022)

Fulltext@MSK | Save

Correlative biomarkers for CART19 response in patients with relapsed or refractory diffuse large B-cell lymphoma

Meeting Abstract

Batlevi, C. L.; Nos, G.; Kotlov, N.; Sorokina, M.; Okwali, M.; Bagaev, A.; Michaud, L.; Shah, G. L.; Shouval, R.; Tomas, A. A.; more...
Blood (2022)

Fulltext@MSK | Save

Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2

Meeting Abstract

Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
Blood (2022)

Fulltext@MSK | Save

Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade

Meeting Abstract

Wills, B.; Michaud, L.; Schöder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
Blood (2021)

Fulltext@MSK | Save

Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)

Meeting Abstract

Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
Blood (2021)

Fulltext@MSK | Save

Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience

Meeting Abstract

Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
Blood (2021)

Fulltext@MSK | Save